Semper Paratus Acquisition (NASDAQ:TVGN) Given “Buy” Rating at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Semper Paratus Acquisition (NASDAQ:TVGN) in a research report report published on Wednesday,Benzinga reports. The firm currently has a $10.00 target price on the stock.

Semper Paratus Acquisition Stock Down 1.6%

Semper Paratus Acquisition stock opened at $1.20 on Wednesday. The firm’s fifty day moving average is $1.15 and its 200 day moving average is $1.20. Semper Paratus Acquisition has a 52-week low of $0.26 and a 52-week high of $3.09.

Insider Buying and Selling

In other news, CEO Ryan H. Saadi sold 1,438,206 shares of the firm’s stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $1.23, for a total value of $1,768,993.38. Following the sale, the chief executive officer now directly owns 116,814,453 shares in the company, valued at approximately $143,681,777.19. This trade represents a 1.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 73.24% of the stock is currently owned by insiders.

Institutional Trading of Semper Paratus Acquisition

Institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. raised its position in Semper Paratus Acquisition by 74.2% during the 4th quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company’s stock worth $40,000 after buying an additional 16,695 shares during the last quarter. Barclays PLC grew its stake in Semper Paratus Acquisition by 39.2% in the 4th quarter. Barclays PLC now owns 45,600 shares of the company’s stock valued at $48,000 after acquiring an additional 12,847 shares during the period. XTX Topco Ltd acquired a new stake in Semper Paratus Acquisition in the 4th quarter valued at $55,000. Nuveen LLC acquired a new stake in Semper Paratus Acquisition in the 1st quarter valued at $97,000. Finally, Northern Trust Corp grew its stake in Semper Paratus Acquisition by 13.0% in the 4th quarter. Northern Trust Corp now owns 118,415 shares of the company’s stock valued at $122,000 after acquiring an additional 13,595 shares during the period.

About Semper Paratus Acquisition

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.